DrugPatentWatch Database Preview
COSMEGEN Drug Profile
see a sample report or, see our see our flat-rate plans
Which patents cover Cosmegen, and what generic alternatives are available?
The generic ingredient in COSMEGEN is dactinomycin. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the dactinomycin profile page.
Summary for COSMEGEN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 24 |
| Patent Applications: | 4,492 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | COSMEGEN at DailyMed |
Pharmacology for COSMEGEN
| Drug Class | Actinomycin |
| Mechanism of Action | Nucleic Acid Synthesis Inhibitors Protein Synthesis Inhibitors |
Medical Subject Heading (MeSH) Categories for COSMEGEN
Synonyms for COSMEGEN
| 050A760 |
| 1-N,9-N-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-6,13-bis(propan-2-yl)-hexadecahydro-1H-pyrrolo[2,1-i]1-oxa-4,7,10,13-tetraazacyclohexadecan-10-yl]-2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxam |
| 15160-EP2272827A1 |
| 15160-EP2275420A1 |
| 15160-EP2280012A2 |
| 15160-EP2281815A1 |
| 15160-EP2289892A1 |
| 15160-EP2292615A1 |
| 15160-EP2295055A2 |
| 15160-EP2295416A2 |
| 15160-EP2295426A1 |
| 15160-EP2295427A1 |
| 15160-EP2298748A2 |
| 15160-EP2298764A1 |
| 15160-EP2298765A1 |
| 15160-EP2301928A1 |
| 15160-EP2301933A1 |
| 15160-EP2305640A2 |
| 15160-EP2305642A2 |
| 15160-EP2305671A1 |
| 15160-EP2308833A2 |
| 15160-EP2311453A1 |
| 15160-EP2311808A1 |
| 15160-EP2311827A1 |
| 15160-EP2311829A1 |
| 15160-EP2311842A2 |
| 15160-EP2316832A1 |
| 15160-EP2316833A1 |
| 1CC1JFE158 |
| 2-Amino- 4,6-dimethyl- 3-oxo- 3H-phenoxazine- 1,9-dicarboxylic acid bis- [(5,12-diisopropyl- 9,13,16-trimethyl- 4,7,11,14,17-pentaoxo- hexadecahydro- 10-oxa- 3a,6,13,16-tetraaza- cyclopentacyclohexadecen- 8-yl)- amide] |
| 2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis-[(18aS)-10c,14,17-trimethyl-5,8,12,15,18-pentaoxo-6c,13t-di(propan-2-yl)-18ar-hexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-9c-yl]-3H-phenoxazine-1,9-dicarboxamid |
| 2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide |
| 2-amino-4,6-dimethyl-3-oxo-N,N'-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxohexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-3H-phenoxazine-1,9-dicarboxamid |
| 2-amino-4,6-dimethyl-3-oxo-N1,N9-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide |
| 2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide |
| 2-amino-N,N''-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-2,5,9,12,15-pentaketo-7,11,14-trimethyl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-3-keto-4,6-dimethyl-phenoxazine-1,9-dicarboxamide |
| 2-amino-N,N''''-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-2,5,9,12,15-pentaketo-7,11,14-trimethyl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-3-keto-4,6-dimethyl-phenoxazine-1,9-dicarboxamide |
| 2-amino-N,N''''''''-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-2,5,9,12,15-pentaketo-7,11,14-trimethyl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-3-keto-4,6-dimethyl-phenoxazine-1,9-dicarboxamide |
| 2-amino-N1,N9-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-phenoxazine-1,9-dicarboxamide |
| 2-azanyl-4,6-dimethyl-3-oxidanylidene-N1,N9-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentakis(oxidanylidene)-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide |
| 3H-Phenoxazine-1,9-dicarboxamide, 2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo- |
| 50-76-0 |
| AB00514445-05 |
| AC1L9W52 |
| ACT [antibiotic] |
| Actactinomycin A IV |
| ActD |
| Actinomycin |
| Actinomycin 7 |
| Actinomycin C1 |
| actinomycin D |
| Actinomycin D, for fluorescence, >=90% (HPLC), from Streptomyces sp. |
| Actinomycin D, from Streptomyces sp., >=95% (HPLC) |
| Actinomycin D, from Streptomyces sp., ~98% (HPLC) |
| Actinomycin D, from Streptomyces sp., suitable for cell culture, >=95% |
| Actinomycin IV |
| AI3-26374 |
| AKOS030228553 |
| BDBM43866 |
| BDBM50089528 |
| BRD-K70578146-001-01-8 |
| CAS-50-76-0 |
| CCG-101134 |
| CHEBI:27666 |
| CHEMBL1554 |
| CHEMBL3792960 |
| cid_457193 |
| Cosmegen Lyovac |
| CPD000469227 |
| CTK8F7580 |
| Dactinomicina |
| DACTINOMYCIN |
| Dactinomycin [USAN:USP:INN:BAN] |
| Dactinomycin, United States Pharmacopeia (USP) Reference Standard |
| Dactinomycine |
| Dactinomycinum |
| DB00970 |
| Dilactone actinomycindioic D acid |
| DSSTox_CID_31 |
| DSSTox_GSID_20031 |
| DSSTox_RID_75330 |
| DTXSID9020031 |
| DVA-DPR-SAR-MVA-(c1)DTH-PXZ-(c11)DTH-DVA-DPR-SAR-MVA |
| EINECS 200-063-6 |
| FT-0080366 |
| Glycopeptide, 4a |
| GNF-Pf-2290 |
| HMS2052O17 |
| Lyovac-Cosmegen |
| Meractinomycin |
| MFCD00005033 |
| MLS001424196 |
| MolPort-003-925-177 |
| NC00384 |
| NCGC00090796-01 |
| NCGC00161622-01 |
| NCGC00161622-02 |
| NCGC00260031-01 |
| NCGC00271789-02 |
| NCI-C04682 |
| NSC 3053 |
| NSC3053 |
| PXZ-THR-DVA-PRO-SAR-MVA-THR-DVA-PRO-SAR-MVA |
| RJURFGZVJUQBHK-IIXSONLDSA-N |
| SAM001246846 |
| SCHEMBL3844 |
| SMR000469227 |
| Specific stereoisomer of N,N'-((2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-diyl)-bis(carbonylimino(2-hydroxypropylidene)carbonyliminoisobutylidenecarbonyl-1,2-pyrrolidinediylcarbonyl(methylimino)methylenecarbonyl))bis(N-me |
| Stereoisomer of N,N'-((2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-diyl)bis(carbonylimino(2-(1-hydroxyethyl)-1-oxo-2,1-ethanediyl)imino(2-(1-methylethyl)-1-oxo-2,1-ethanediyl)-1,2-pyrrolidinediylcarbonyl(methylimino) (1-oxo |
| Tox21_111997 |
| Tox21_111997_1 |
| Tox21_202482 |
| UNII-0OCC969V50 component RJURFGZVJUQBHK-IIXSONLDSA-N |
| UNII-1CC1JFE158 |
| UPCMLD-DP055 |
| UPCMLD-DP055:001 |
| UPCMLD-DP055:002 |
US Patents and Regulatory Information for COSMEGEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Recordati Rare | COSMEGEN | dactinomycin | INJECTABLE;INJECTION | 050682-001 | Approved Prior to Jan 1, 1982 | AP | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
see a sample report or, see our see our flat-rate plans
